---
title: "Iterum Therapeutics plc SEC 10-K Report"
date: "2025-02-07 20:38:00"
summary: "Iterum Therapeutics plc, a pharmaceutical company focused on developing and commercializing anti-infectives, has released its annual Form 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it faces. Financial Highlights Total Operating Expenses: $18.7 million, reflecting a decrease from..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Iterum Therapeutics plc, a pharmaceutical company focused on developing and commercializing anti-infectives, has released its annual Form 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it faces.

**Financial Highlights**

* **Total Operating Expenses**: $18.7 million, reflecting a decrease from $47.5 million in 2023, primarily due to reduced research and development expenses.
* **Operating Loss**: $18.7 million, improved from $47.5 million in 2023, driven by cost reductions in research and development.
* **Net Loss**: $24.8 million, compared to $38.4 million in 2023, indicating a reduction in losses due to decreased operating expenses.
* **Net Loss Per Share**: $1.26, down from $2.96 in 2023, reflecting the impact of reduced net loss on a per-share basis.

**Business Highlights**

* **Product Launch**: The company launched ORLYNVAH™, the first oral branded penem available in the United States, approved by the FDA for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.
* **Regulatory Approval**: On October 25, 2024, the FDA approved the New Drug Application (NDA) for ORLYNVAH™ for treating uUTIs caused by specific microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
* **Clinical Trials**: The REASSURE Phase 3 clinical trial demonstrated that ORLYNVAH™ met the primary endpoint of statistical non-inferiority to Augmentin® and showed statistically significant superiority in the Augmentin® susceptible population.
* **Intellectual Property**: The company holds multiple patents related to sulopenem and its formulations, with expiration dates ranging from 2039 to 2041, and has pending patent applications in various jurisdictions.
* **Strategic Focus**: The company is exploring strategic options to sell, license, or otherwise dispose of its rights to sulopenem to maximize stakeholder value, while also considering commercialization strategies in the United States.
* **Market Opportunity**: There is a significant unmet medical need for new oral antibacterial therapies due to increasing antimicrobial resistance, particularly for uUTIs, with ORLYNVAH™ positioned to address this need.
* **Future Development**: The company plans to pursue additional indications for its sulopenem program, including complicated urinary tract infections (cUTIs) and other bacterial infections, and is considering regulatory strategies outside the United States.
* **Manufacturing Capability**: The company has established a manufacturing program for sulopenem, with registered contract manufacturing organizations to produce the active pharmaceutical ingredient for ORLYNVAH™.
* **Competitive Advantage**: ORLYNVAH™ offers a broad range of activity against resistant and multi-drug resistant gram-negative bacteria, with a favorable safety and tolerability profile, and convenient oral dosing.

**Strategic Initiatives**

* **Strategic Initiatives**: The company is focused on maximizing the commercial potential of ORLYNVAH™, the first oral branded penem available in the U.S., and is exploring strategic alternatives to sell, license, or otherwise dispose of its rights to sulopenem. This includes engaging a financial advisor to assist in evaluating various strategic alternatives. The company is also considering options for commercializing ORLYNVAH™ in the U.S. with a commercial partner or on its own with a targeted sales force.
* **Capital Management**: The company has engaged in several capital management activities, including the issuance of ordinary shares and warrants through various offerings such as the 2024 Rights Offering, which raised net proceeds of $5.4 million. Additionally, the company has utilized an 'at the market offering' agreement to sell ordinary shares, raising $19.4 million in net proceeds. The company has also managed its debt through the issuance of Exchangeable Notes and Royalty-Linked Notes, with a focus on managing liabilities and raising capital through equity and debt financings.
* **Future Outlook**: The company plans to continue its strategic process to sell, license, or otherwise dispose of its rights to sulopenem to maximize shareholder value. If this process does not result in a transaction, the company may seek to commercialize ORLYNVAH™ in the U.S. with a commercial partner or independently. The company acknowledges the need for additional capital to fund operations and is exploring various financing options, including public or private equity offerings, debt financings, and strategic alliances. The company is also evaluating corporate, strategic, financial, and financing alternatives to maximize shareholder value.

**Challenges and Risks**

* **Strategic and Financial Risks**: The company faces significant risks related to its strategic options and financial position. The exploration of strategic alternatives, including the sale or licensing of sulopenem, may not be successful, potentially leading to liquidation and dissolution if viable options are not identified. The company's financial position is precarious, with substantial doubt about its ability to continue as a going concern due to limited cash resources and the need for additional funding to support operations and commercialization efforts.
* **Operational Risks**: The company has incurred net losses since inception and anticipates continued losses unless it successfully commercializes its sulopenem program. The financial strategy involves raising capital through equity offerings, debt financings, and other means, but there is no assurance of success. The company's indebtedness imposes restrictions that could hinder additional capital raising efforts. Operational risks include the potential failure to commercialize ORLYNVAH™ successfully, which is critical for generating revenue. The company lacks a commercial organization and may face challenges in establishing sales, marketing, and distribution capabilities. Additionally, the company is heavily dependent on the success of ORLYNVAH™ and sulopenem, with significant risks if these products do not achieve market acceptance or if bacterial resistance develops.
* **Regulatory Risks**: The company must obtain and maintain marketing approvals for its products. The development and commercialization of sulopenem are subject to regulatory scrutiny, and any adverse findings could delay or prevent product approval. The company also faces potential product liability claims related to its clinical trials and product candidates.
* **Market Risks**: The company is exposed to market risks, including fluctuations in foreign currency exchange rates, which could adversely affect financial results. Additionally, the company faces risks related to the valuation of derivative instruments, which can result in significant non-operating gains or losses due to changes in management's assumptions and market conditions.

SEC Filing: [Iterum Therapeutics plc [ ITRM ] - 10-K - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm)

[TradingView](https://www.tradingview.com/news/tradingview:ddfa71b17dd9a:0-iterum-therapeutics-plc-sec-10-k-report/)
